dimethylmalonic acid : A dicarboxylic acid that is malonic acid in which both methylene hydrogens have been replaced by methyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 11686 |
| CHEMBL ID | 3360549 |
| CHEBI ID | 111517 |
| SCHEMBL ID | 52160 |
| MeSH ID | M0232437 |
| Synonym |
|---|
| nsc 836 |
| propanedioic acid, 2,2-dimethyl- |
| 2,2-dimethylmalonate |
| unii-55981wkx6b |
| hydrogen 2,2-dimethylmalonate |
| 55981wkx6b , |
| einecs 209-867-1 |
| chembl3360549 , |
| bdbm50038339 |
| propanedioic acid dimethyl |
| inchi=1/c5h8o4/c1-5(2,3(6)7)4(8)9/h1-2h3,(h,6,7)(h,8,9 |
| 2,2-dimethylmalonic acid |
| AQ-917/40386832 |
| 595-46-0 |
| propanedioic acid, dimethyl- |
| dimethylmalonic acid |
| nsc836 |
| malonic acid, dimethyl- |
| 2,2-propanedicarboxylic acid |
| nsc-836 |
| dimethylmalonic acid, 98% |
| CHEBI:111517 |
| dimethylpropanedioic acid |
| 2,2-dimethylpropanedioic acid |
| D2606 |
| 2,2-dimethyl-propanedioic acid |
| LMFA01170103 |
| dimethyl-malonic acid |
| A832359 |
| AKOS005255257 |
| FT-0632477 |
| AM20100452 |
| SCHEMBL52160 |
| OREAFAJWWJHCOT-UHFFFAOYSA-N |
| DTXSID5060489 |
| SY016494 |
| mfcd00004193 |
| AC-22740 |
| Q27191232 |
| F8881-3077 |
| J-520371 |
| CS-W007894 |
| dimethylmalonic acid, standard for quantitative nmr, tracecert(r) |
| 2,2-propanedicarboxylate |
| dimethylmalonsa currencyure |
| dimethyl malonic acid |
| AS-12448 |
| 4-acetoxy-biphenyl-4-carboxylicacid |
| HY-W007894 |
| MU6 , |
| EN300-37489 |
| Role | Description |
|---|---|
| fatty acid synthesis inhibitor | Any pathway inhibitor that inhibits the synthesis of fatty acids. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dicarboxylic acid | Any carboxylic acid containing two carboxy groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1174256 | Inhibition of mouse serine racemase using L-serine substrate by reversed-phase HPLC analysis | 2015 | European journal of medicinal chemistry, Jan-07, Volume: 89 | Malonate-based inhibitors of mammalian serine racemase: kinetic characterization and structure-based computational study. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||